This Fund Logs $63M Bet on Chemours Even as Shares Remain ≈80% Below 2017 Highs

A New York‑based investment firm, Cooper Creek Partners Management, quietly opened a position in The Chemours Company (NYSE: CC), acquiring nearly 4 million shares in the third quarter. The move was disclosed in an SEC filing dated November 14. By September 30, the stake was valued at roughly US$63.1 million, amounting to about 1.9% of the fund’s U.S. equity portfolio — which totals around US$3.3 billion across 88 positions. What stands out: Chemours’ stock has struggled. This year alone it’s dropped over 40%, and its share price remains almost 80% below its 2017 peak. So why buy now? The fund’s move suggests conviction in a potential rebound — perhaps betting on stabilization in Chemours’ business fundamentals, cost control, or future commodity demand. It also signals that some investors view the current low valuation as an attractive entry point, assuming the chemicals market recovers or the company addresses its headwinds. That said, the steep discount vs. past highs underscores the risk: if underlying challenges persist (e.g. weak demand, commodity pricing, regulatory or environmental pressures), the recovery might be slow or nonexistent. Investors watching this stock should treat the new stake as a calculated — and speculative — bet on a turnaround. #InvestingNews #Chemours #ValueStock #WallStreetMoves #SlimScan #GrowthStocks #CANSLIM